The absence of drugs to target the Sars-CoV-2 virus had triggered research on repurposed drugs, as well as biologics
Convalescent plasma (plasma-derived therapy) from Covid-19 patients and products derived from it have failed to get a thumbs up from the expert panel advising the Indian drug regulator on Covid vaccines and drugs.
The subject expert committee (SEC) noted recently that clinical trials on the convalescent plasma in Mumbai’s Wockhardt Hospitals and on hyperimmune globulins by Intas Pharmaceuticals (Intas) have not shown any remarkable difference in efficacy between the treatment and control arms. The panel has rejected Intas’ application for restricted emergency-use authorisation for the blood product.
The absence of drugs to target the Sars-CoV-2 virus had triggered research on repurposed drugs, as well as biologics. Immunity modulating products derived from convalescent plasma (part of blood) were put to test to see if it worked to treat Covid-19 patients.
Ahmedabad-based Intas had initiated work on what they call Covid-19 hyperimmune globulins. A patient who has recovered from Covid has antibodies that are targeted against the virus. In convalescent plasma therapy, these Sars-CoV-2-neutralising antibodies containing plasma are administered to a patient. The Covid-19 hyperimmune globulin product is also prepared from convalescent plasma.
No comments:
Post a Comment